PTC Therapeutics, Inc.

Valuation Analysis

About the Company

PTC Therapeutics, Inc. en bref

PTC Therapeutics, Inc. (PTCT) is currently trading at 68,85 € with a market capitalization of 5,7 Md €. The 52-week range spans from 37,63 € to 76,28 €; the current price is 9.7% below the yearly high. Year-over-year revenue growth stands at -76.8%.

💰 Dividende

PTC Therapeutics, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent PTC Therapeutics, Inc. (PTCT) au consensus : Acheter. L'objectif de cours moyen est de 81,88 €, soit un potentiel de +18.93% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 56,66 € à 108,10 €.

PTC Therapeutics, Inc. : la thèse d'investissement en détail

PTC Therapeutics, Inc. (PTCT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 18.93% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -76.8% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 17.48% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (17.48%).

Trading Data

Related Stocks in the Same Sector

Where can I buy PTC Therapeutics, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.